CNS metastases

CNS metastases

Central nervous system metastases, see there.
References in periodicals archive ?
There was 1 fatal intracranial hemorrhage case among 16 patients who received LENVIMA and had CNS metastases at baseline.
However, a recent retrospective analysis of more than 12 000 patients determined that the risk of cerebral hemorrhage is not disproportionately higher in patients with CNS metastases and suggested that the administration of bevacizumab should no longer be contraindicated based solely on the presence of brain metastasis (58).
Burstein reported that about 10% of trastuzumab-treated women with metastatic breast cancer develop isolated CNS metastases.
For example, patients with recurrent CNS metastases from breast cancer, CNS lymphoma, or carcinomatous/lymphomatous meningitis can be treated with a high-dose methotrexate regimen.
There was one case of fatal intracranial hemorrhage among 16 patients who received LENVIMA and had CNS metastases at baseline.
We therefore compared the diagnostic accuracy of the monoclonal TPS and the polyclonal TPA tests in terms of identifying and excluding CNS metastases among breast cancer patients, following recent guidelines for reporting studies of diagnostic accuracy of medical tests (11).
Patients with treated stable central nervous system (CNS) metastases are eligible for the dose escalation portions of the trial, while patients with CNS metastases which are either asymptomatic and untreated or progressive following local therapy may be included in the expansion cohorts.
We elected to expand cohort three to gather additional data on patients with CNS metastases of solid tumors in order to solidify our plans for further development of this important drug candidate.
Results from an ongoing, multicenter Phase II study suggest that TYKERB has clinical activity in heavily pretreated patients with CNS metastases from HER2-positive breast cancer.
The trial evaluated Tykerb in 39 patients with ErbB2 positive breast cancer who had developed CNS metastases while on trastuzumab.
Two additional published studies provide further evidence of low local recurrence rates when GLIADEL is used in combination with initial surgical resection of CNS metastases and other therapies, however, randomized, controlled clinical trials are needed to confirm these findings before any conclusions about efficacy can be drawn.
Recognition that lung cancer patients with CNS metastases are more amenable to treatments aimed at delaying neurologic progression is an important discovery that we look forward to investigating and confirming.